Co-developed by NYU Langone and Dana-Farber, the Solavia platform integrates EHR workflows, decision support, and pathway tracking for APPs and PAs.
|Articles|July 6, 2015
Dr. Andrew M. Kaunitz on Considerations for Previvors in Addressing Menopausal Symptoms
Author(s)Andrew M. Kaunitz, MD, FACOG
Andrew M. Kaunitz, MD, FACOG, discusses important considerations for previvors in addressing menopausal symptoms.
Advertisement
Andrew M. Kaunitz, MD, FACOG, professor, Associate Chair, Department of Obstetrics and Gynecology, University of Florida College of Medicine — Jacksonville, discusses important considerations for previvors in addressing menopausal symptoms.
Advertisement
Related to this article
The FDA expands accelerated approval for sevabertinib to frontline HER2-mutant NSCLC, highlighting a need for vigilant nursing management of diarrhea.
FDA approves camizestrant for ESR1-mutated advanced breast cancer, tasking oncology nurses with guiding patients through ctDNA-based surveillance.
Dana Delaski, MSN, FNP-BC, shares insights on how once-daily ruxolitinib, self-injected rusfertide, and givinostat will transform PV clinic workflows.
The FDA has approved oral iberdomide (Zenbexus) for relapsed/refractory multiple myeloma, offering patients a highly potent, accessible therapy.
Oncology clinicians must actively champion NCCN guidelines as a critical pillar of breast cancer survivorship care,
With daraxonrasib approved for metastatic pancreatic cancer, Yolanda Justal, APRN, discusses essential nursing workflows for home-based care.
Beth Sandy, CRNP, of Penn Medicine explains how oncology nurses and pharmacists collaborate to manage financial toxicity and secure oral therapies.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated, ER-Positive, HER2-Negative Advanced Breast Cancer
2
Prostate Cancer Care: ADT Management and APP Guidance
3
Why Using AI to Interpret Mammogram Results Can Cause Unnecessary Panic
4
WCLC 2026: Oncology Nursing Takeaways on Supportive Care and APP-Led Models
5